November 19, 2013
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

EnglishTranslation

SymBio Announces Issuance of New Shares and Secondary Offering of Shares
TOKYO, Japan, November 19, 2013 -- SymBio Pharmaceuticals Limited (JASDAQ: 4582, hereinafterreferred to as “the Company”) announced today that the following resolution regarding the issuance of newshares and the secondary offering of the Company’s shares in Japan was adopted at the meeting of theBoard of Directors held on November 19, 2013.
Details of the issuance are stated below:1. Issuance of New Shares and Secondary Offering of Shares(1) New share issue through the public offering(1) Number of offering shares

6,720,200 common shares(2) Amount to be paid

The amount to be paid will be determined on a day (the“Determination Date”) during the period from Wednesday,November 27, 2013 to Monday, December 2, 2013 inaccordance with the method stated in Article 25 of theRegulations concerning Underwriting of Securities, etc. of theJapan Securities Dealer Association (“JSDA”).

(3) Amount of capital and additional
paid-in capital to be increased

The amount of capital to be increased shall be half of themaximum amount of capital increase, as calculated in accordancewith Article 14, Paragraph 1 of the Rules of Account Settlement ofCorporations with any fraction less than one yen resulting from thecalculation being rounded up to the nearest one yen. The amountof additional paid- in capital to be increased shall be the amountobtained by subtracting the relevant amount of capital to beincreased from the relevant maximum amount of capital increase.

(4) Method of offering

The offering of the issuance of new shares shall be conductedthrough a public offering. SMBC Nikko Securities Inc. shallunderwrite and purchase all of the shares. The issue price (offerprice) shall be determined on the Determination Date based on
the tentative pricing range calculated by multiplying the closing
price in ordinary market transactions of Company’s common stock
in regular trading on the Tokyo Stock Exchange on theDetermination Date (or, if no closing price is quoted, the closing
price of the immediate preceding date) by 0.90 -1.00 (with anyfraction less than one yen being rounded down), in accordancewith the method stated in Article 25 of the Regulations concerning
Underwriting of Securities, etc. of the JSDA, taking into accountmarket demand and other conditions.

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offeringof shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. Thispress release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press
release is not an offer of securities for sale in the United States. The securities have not and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act. No offering of securities in the UnitedStates will be made in connection with the above mentioned transactions.

(5) Considerations for underwriter

The Company shall not pay any underwriting commissions to theunderwriter, although the aggregate amount of the difference
between (a) the issue price (offer price) and (b) the amount to be
paid to the Company by the underwriter shall constitute proceeds
to the underwriter.

(6) Subscription Period

The subscription period shall be from the business day
immediately following the Determination Date to the second
business day immediately following the Determination Date.

(7) Payment Date

The payment date shall be a day during the period from
Wednesday, December 4, 2013 to Monday, December 9, 2013,that is the fifth business day immediately following theDetermination Date.

(8) Delivery Date

The business day immediately following the Payment Date

(9) Subscription unit

100 shares(10) Deposit for subscription

Amount equal to the issue price per share(11)Others

Determination of the amount to be paid, the amount of capital andadditional paid-in capital to be increased, the issue price (offerprice) and all other matters necessary for the issuance of newshares through the public offering shall be left to the discretion of
the Representative Director, President and Chief ExecutiveOfficer.
The public offering related to the issuance of new shares shall beconditional upon the securities registration statement filed under
the Financial Instruments and Exchange Act of Japan becoming
effective.

(2) Secondary Offering (Over-allotments)
1,008,000 common shares
The number of shares mentioned above is the maximum numberof shares to be sold. The above number may decrease, or the(1) Number of shares for secondary secondary offering to cover over-allotments may be cancelledentirely, depending on market demand and other conditions. Theoffering
number of shares to be sold shall be determined on theDetermination Date, taking into account market demand and otherconditions.
(2) Offering party

SMBC Nikko Securities Inc.

(3) Secondary offering priceUndetermined. (The selling price will be determined on theDetermination Date; provided, however, that such selling priceshall be the same as the issue price (offer price) in respect of theissuance of new shares through the public offering.

(4) Method of secondary offering

Taking into account market demand and other conditions, SMBC
Nikko Securities Inc., the lead manager of the public offering, will
make a necessary secondary offering of the shares that it willborrow from certain shareholder (s) of the Company.

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offeringof shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. Thispress release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press
release is not an offer of securities for sale in the United States. The securities have not and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act. No offering of securities in the UnitedStates will be made in connection with the above mentioned transactions.

(5) Subscription Period

The Subscription period to cover over-allotments shall be thesame as the Subscription Period of the new share issue throughthe public offering.

(6) Delivery date

The Delivery Date shall be the same as the Delivery Date of thenew share issue through the public offering.

(7) Deposit for subscription

Amount equal to the issue price per share(8) Subscription unit

100 shares
Determination of the selling price and all other matters necessary
for the secondary offering to cover over-allotments shall be left tothe discretion of the Representative Director, President and Chief
Executive Officer.

(9) Others
The secondary offering to cover over-allotments shall be
conditional upon the securities registration statement filed under
the Financial Instruments and Exchange Act of Japan becoming
effective.
(3) Issuance of new shares by way of third-party allotment(1) Number of new shares

1,008,000 common shares(2) Amount to be paid

The amount to be paid shall be the same as the amount to be paidin with respect to new share issue through the public offering(3) Amount of capital and additional
paid-in capital to be increased

The amount of capital to be increased shall be half of themaximum amount of capital increase, as calculated in accordancewith Article 14, Paragraph 1 of the Rules of Account Settlement ofCorporations with any fraction less than one yen resulting from thecalculation being rounded up to the nearest one yen. The amountof additional paid- in capital to be increased shall be the amountobtained by subtracting the relevant amount of capital to be
increased from the relevant maximum amount of capital increase.

(4) Allottee

SMBC Nikko Securities Inc.

(5) Subscription Period

Tuesday, December 24, 2013(6) Payment Date

Wednesday, December 25, 2013(7) Subscription unit

100 shares(8)Others

Determination of the amount to be paid, the amount of capital andadditional paid-in capital to be increased, and all other mattersnecessary for the issuance of new shares by way of third party
allotment shall be left to the discretion of the Representative
Director, President and Chief Executive Officer.
The issuance of new shares by way of third-party allotment shallbe conditional upon the securities
registration statement filed under the Financial Instruments andExchange Act of Japan becoming effective.

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offeringof shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. Thispress release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press
release is not an offer of securities for sale in the United States. The securities have not and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act. No offering of securities in the UnitedStates will be made in connection with the above mentioned transactions.

2.

Use of Funds RaisedThis fund will be allocated during a period from January, 2014 through December, 2015 toward
development expenses for SyB L-1101 (rigosertib, intravenous) for treating relapsed and refractory
Myelodysplastic Syndromes (MDS) and SyB C-1101 (rigosertib, oral agent) for the initial treatment ofMDS. Proceeds will also be used to fund development and milestone payments for SyB
L/C-1101(rigosertib, intravenous and oral agent) in additional indications outside of MDS.
Until specific financial needs arise, it is our policy to manage this fund by, among other methods,investing it in low risk financial instruments.

【Background and Purpose of the Offering】
Research and development of new orphan drugs in the fields of cancers, hematology and autoimmune
diseases are being increasingly investigated by many universities, laboratories and bio-ventures rather thanmajor pharmaceutical companies, particularly in Europe and the U.S. providing many effective new drugcandidates. However, the development of drugs in those fields is very challenging, requiring a high degreeof specialization and economic stability and liberty. As a consequence, in Asian countries including Japan,
these fields are considered “underserved therapeutic areas” that have been virtually untapped.
Since its foundation, SymBio has worked on the development of new drugs in these areas, focusing oncancers, hematology and autoimmune diseases, which pose a high barrier to entry.
Currently the Company has three drug candidates for development and commercialization in SyB L-0501(TREAKISYM®), SyB L-1101 (rigosertib: intravenous), and SyB C-1101 (rigosertib: oral).
With regard to TREAKISYM®, the company acquired the approval for marketing in Japan in October, 2010
in order to apply for the treatment of relapsed/refractory low-grade non-Hodgkin's lymphoma and mantle celllymphoma. Encouraging treatment results have been already gained from more than 7,000 patients of thediseases since the launch in December, 2010. The Company is currently advancing the development withthis agent further in order to acquire an approval for new application for the treatment of other diseases
including frontline low-grade non-Hodgkin's lymphoma.
Further, the Company in-licensed an anti-cancer agent rigosertib from a U.S company Onconova
Therapeutics, Inc. in July, 2011. Phase I clinical trials of intravenous and oral rigosertib (SyB C-1101) are
ongoing in relapsed/refractory Myelodysplastic Syndromes (MDS) and frontline Myelodysplastic Syndrome,respectively. The licenser Onconova is advancing the development with this agent for its application for thetreatment of some solid tumors as additional indications.
(Note) 1 SyB L-1101, SyB C-1101, and SyB L/C-1101 are the development codes in the Company.
2 Myelodysplastic Syndromes (MDS) represent a group of diverse myeloid (bone marrow) stem
cell disorders that gradually affect the ability of bone marrow to produce red blood cells, whiteblood cells and platelets sufficiently. Blood stem cells fail to mature into healthy blood cells, andthe immature blood cells, called blasts, do not function normally and either die in the bonemarrow or enter the blood. A higher percent of blasts is linked to a higher likelihood ofdeveloping acute myeloid leukemia and poorer overall prognosis. The risk of MDS increases
with age and the disease commonly affects the elderly. In Japan, the number of the patients is
estimated to be around 11,000 (according to the survey of patients by the Ministry of Health,Labour and Welfare in 2011). At present, there is only one therapeutic agent sold as aNote: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offeringof shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. Thispress release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press
release is not an offer of securities for sale in the United States. The securities have not and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act. No offering of securities in the UnitedStates will be made in connection with the above mentioned transactions.

treatment for MDS, and therefore the patients are waiting for a new medical agent for thedisease to be developed.
3 The patients of relapsed/refractory diseases are classified into ones who have developed
resistance to the initial treatment, ones who haven’t developed resistance to the treatment but
relapsed, and ones who have relapsed and developed resistance to the treatment.
4 The “milestone” refers to a lump-sum paid to Onconova Therapeutics, the licenser, under theLicense Agreement when successful events such as acquiring an approval occur.
5 Onconova Therapeutics, based in the U.S. States of Pennsylvania and New Jersey, is apharmaceutical company specializing in biopharmaceuticals. Focusing on cancer treatment
and protection of healthy cell since its foundation in 1998, this company has discovered andoptimized novel small molecule therapeutics aiming at new molecular and biological therapies,
based on its extensive proprietary chemical library comprising more than 125 new drug
development candidates for chemotherapy treatments.

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals was established in March, 2005, by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan (currently Takeda Bio
Development Center Limited). The company’s underlying corporate mission is “delivering hope to patients inneed” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated toaddressing underserved medical needs with focus in oncology, hematology and autoimmune disease.

[Contact]
Tomoyuki Watanabe
Director, Head of Corporate Planning Division
Tel: +081(0)3 5472 1125

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to the Offeringof shares of the Company and not for the purpose of soliciting investment or engaging in any other similar activity. Thispress release does not constitute an offer of any securities for sale within or outside Japan. Additionally, this press
release is not an offer of securities for sale in the United States. The securities have not and will not be registered under
the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States
absent registration or an exemption from registration under the Securities Act. No offering of securities in the UnitedStates will be made in connection with the above mentioned transactions.